Final results of the EORTC 18871/DKG 80-1 randomised phase III trial
Ulrich R. Kleeberg(European Organisation for Research and Treatment of Cancer), A.M.M. Eggermont(Praxis für Hämatologie und Onkologie), D. J. Ruiter(Radboud University Nijmegen), Stefan Suciu(St James's University Hospital), E.‐B. Bröcker, J.R. Marsden(Birmingham General Hospital), Cécile Chartier(Io Therapeutics (United States)), D. Liénard, Dirk Schadendorf(National Center for Tumor Diseases)
Cited by 240
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
|Science|2016|3.1k
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
|New England Journal of Medicine|2014|2.7k